Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
Launched by HOSPITAL CLINIC OF BARCELONA · Feb 6, 2006
Trial Information
Current as of August 30, 2025
Suspended
Keywords
ClinConnect Summary
Phase 3
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with HRS type 1 or 2 with serum creatinine \>2 mg/dL
- • 2. Age between 18 and 75 years
- • 3. Written informed consent.
- • 4. Absence of exclusion criteria
- Exclusion Criteria:
- • 1. Hepatocarcinoma (3 nodules greater than 3 cm or 1 nodule \> than 5 cm)
- • 2. Active infection with systemic inflammatory response syndrome
- • 3. Respiratory or cardiac dysfunction.
- • 4. Arteriopathy.
- • 5. Ischemic cardiopathy.
- • 6. Arterial hypertension ( \>140/90 mmHg during hospitalization )
About Hospital Clinic Of Barcelona
The Hospital Clinic of Barcelona is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry to enhance patient outcomes. As a prominent sponsor of clinical trials, the Hospital Clinic of Barcelona is dedicated to exploring new therapies and treatment modalities across various medical fields, fostering a culture of excellence in clinical research that ultimately aims to improve the quality of care for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
Pere Gines, MD
Principal Investigator
Chair of Liver Unit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials